Aesica Recruits Technical Director and Two New Business Development Managers - - BioPharm International

ADVERTISEMENT

Aesica Recruits Technical Director and Two New Business Development Managers


Aesica, a contract development and manufacturing organization (CDMO), announced that it has appointed Bashir Hansraj as global technical director. Based at Aesica’s Newcastle headquarters in the UK, Hansraj will be responsible for developing global lead technical centers for API development, drug product development and technology innovation. The technical centers will be dedicated to specific dosage forms including oral solids, oral liquids, topicals, inhalation and parenterals.

Hansraj has more than 30 years of experience in the pharmaceutical industry, having held senior management R&D roles within Pfizer Consumer Healthcare, J&J, Pfizer Global R&D and most recently, at Catalent where he was head of R&D. In addition to life science degrees, Hansraj also has an MBA and, in his previous roles, led the development and commercialization of many leading brands utilizing various technology platforms.

Aesica also recently appointed two new business development managers, David Ross and Sven Thomas, as part of the company’s strategic drive to further revenues growth in Europe. Their appointment is the next phase in the company’s strategy to increase sales from its integrated API, formulation development and manufacturing services and they will be responsible for ensuring potential customers are clearly aware of how the company can support their manufacturing and development needs. David Ross will focus on the UK, Ireland and Scandinavia whilst Sven Thomas will handle Central and Eastern Europe with a strong emphasis on expanding the level of business from Germany and the growing economies in Eastern Europe. Ross has experience in contract research and contract manufacturing with Patheon, Catalant and Ipsen, whereas Thomas who previously worked for UCB, brings to the table his breadth of pharmaceutical manufacturing expertise.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines

Click here